Sumeet Mitter, MD
Cardiovascular Disease · New York, NYNPI 1912221896
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 34.0% of the total. 2025 is the largest year on record at $98,712, more than ten times the $8,961 reported in 2019. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $702.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$53K
- Pfizer$31K
- Novo Nordisk AS$25K
- Bridgebio Pharma, Inc.$16K
- Novo Nordisk$13K
- Abbott$12K
- plus $6K from 20 others
Across 32 payments — averaging $20,306 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$392K
- AstraZeneca$228K
- Eidos Therapeutics, Inc.$28K
- Pfizer$1K
What the payments were for
- Consulting fees$69,00945%
- Speaking & faculty fees$57,56637%
- Travel & lodging$18,98712%
- Food & beverage$8,9346%
- Education$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 49 | $52,588 |
| Pfizer | 25 | $30,606 |
| Novo Nordisk AS | 6 | $24,525 |
| Bridgebio Pharma, Inc. | 6 | $16,275 |
| Novo Nordisk | 7 | $12,763 |
| Abbott | 63 | $11,886 |
| AstraZeneca(2 entities) | 20 | $3,995 |
| Boston Scientific | 5 | $270 |
| Endotronix, Inc. | 1 | $240 |
| Akcea Therapeutics, Inc. | 3 | $226 |
| Atricure, Inc. | 3 | $225 |
| E.r. Squibb & Sons, L.L.C. | 10 | $223 |
| Abiomed | 1 | $129 |
| Tris Pharma Inc | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $99 |
| Daxor Corporation | 1 | $79 |
| Boehringer Ingelheim | 3 | $78 |
| Lexicon Pharmaceuticals, Inc. | 3 | $66 |
| Novartis | 3 | $65 |
| Johnson & Johnson | 2 | $60 |
| Merck | 2 | $39 |
| United Therapeutics Corporation | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Eurofins Viracor, LLC | 1 | $16 |
| Invivyd Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMVUTTRA$29,780
- VYNDAQEL$18,136
- Attruby$16,275
- VYNDAMAX$12,218
- CardioMEMS HF System$9,123
- ONPATTRO$3,375
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$704
- CARDIOMEMS$616
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$240
- MitraClip System$234
- SYNERGY ABLATION SYSTEM$141
- Impella$129
- TEGSEDI$101
How this compares
$154,658 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 84 | $2,341,625 |
| VyndaqelTafamidis Meglumine | 12 | $274,890 |
| JardianceEmpagliflozin | 27 | $35,124 |
| EntrestoSacubitril/Valsartan | 17 | $30,164 |
| FarxigaDapagliflozin Propanediol | 20 | $27,447 |
| Atorvastatin Calcium | 20 | $347 |
| Furosemide | 17 | $257 |
| Carvedilol | 29 | $226 |
| Torsemide | 15 | $220 |
| Spironolactone | 29 | $209 |
| Metoprolol Succinate | 14 | $205 |
| Amlodipine Besylate | 13 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel | $30,606 | $2,616,51596 claims |
| Boehringer IngelheimJardiance | $78 | $35,12427 claims |
| NovartisEntresto | $65 | $30,16417 claims |
| AstraZenecaFarxiga | $3,995 | $27,44720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.